| MTD |
Report |
Q2 adjusted EPS |
BEAT |
pred ~$10.94 vs. cons $10.80 |
MEDIUM |
| MTD |
Report |
Q2 revenue |
IN-LINE |
pred ~$1.039B vs. cons $1.038B |
MEDIUM |
| MTD |
Report |
Q2 local-currency sales growth |
BEAT |
pred ~3.5% vs. cons 3.0% |
MEDIUM |
| MTD |
Guide |
Q3 adjusted EPS |
BETTER |
guide ~$12.10 vs. cons $12.08 (Q3 2026) |
LOW |
| MTD |
Guide |
Q3 local-currency sales growth |
UNCHANGED |
guide ~5.0% vs. cons 5.0% (Q3 2026) |
MEDIUM |
| MTD |
Guide |
Full-year adjusted EPS |
BETTER |
guide ~$46.80 vs. cons $46.67 (FY 2026) |
MEDIUM |
| MTD |
Guide |
Full-year local-currency sales growth |
UNCHANGED |
guide ~4.0% vs. cons 4.0% (FY 2026) |
HIGH |
| MTD |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.3% |
— |
MEDIUM |
| MTD |
Return |
5-day cumulative residual |
+1.2% (FADE) |
Initial relief from Q2 adjusted EPS of ~$10.94 versus ~$10.80 consensus should be partly offset as the FY 2026 guide of ~$46.80 versus ~$46.67 consensus produces only modest estimate revisions and still requires a second-half organic acceleration. |
MEDIUM |